A trial-based economic evaluation of peppermint oil for the treatment of irritable bowel syndrome.
Zsa Zsa R M WeertsBrigitte A B EssersDaisy M A E JonkersJeresa I A WillemsDeborah J P A JanssenBen J M WittemanCees H M ClemensAudrey WestendorpAdrian A M MascleeDaniel KeszthelyiPublished in: United European gastroenterology journal (2021)
In patients with IBS, small-intestinal release peppermint oil appears to be a cost-effective treatment although there is uncertainty surrounding the ICER. When using abdominal pain responder as outcome measure for the ICER, peppermint oil has a high probability of being cost-effective. The use of peppermint oil, which is a low-cost treatment, can be justified by the modest QALY gains and slightly higher proportion of abdominal pain responders. More research and long-term data are necessary to confirm the cost-effectiveness of peppermint oil. NCT02716285.